Literature DB >> 15912390

Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients.

Tuomo Nieminen1, Hannu Uusitalo, Väinö Turjanmaa, Gunilla Bjärnhall, Hans Hedenström, Jukka Mäenpää, Auli Ropo, Pekka Heikkilä, Mika Kähönen.   

Abstract

OBJECTIVES: The aims of the study were to assess the correlation between the plasma concentration of ophthalmic timolol and cardiovascular parameters, and the influence of timolol on advanced haemodynamic variables, such as stroke (SI), cardiac (CI) and systemic vascular resistance (SVRI) indices and arterial pulse wave velocity (PWV).
METHODS: Twenty-five glaucoma or ocular hypertensive patients were treated with 0.5% aqueous and 0.1% hydrogel formulations of timolol using a randomised, double-masked, crossover, multicentre design. All the patients were subjected to passive head-up tilt, electrocardiography, exercise test and measurement of plasma concentration of timolol. In the analysis, the data on the two treatments were combined, and the Spearman correlation coefficients between the plasma level of timolol and physiological effects were calculated.
RESULTS: During the head-up tilt test before rising the bed up, the resting heart rate (HR; R=-0.52, P=0.001) and PWV (R=-0.34, P=0.04) were inversely correlated with timolol level. In the upright position, ophthalmic timolol effectively suppressed the rise in HR (R=-0.36, P=0.03). The SI did not change with timolol concentration, while CI diminished as timolol concentration rose (R=-0.39, P=0.02). The SVRI correlated with timolol concentration (R=0.38, P=0.02). In the exercise test, correlation between HR and plasma level of timolol steadily grew stronger as the load increased, reaching R=-0.60 (P<0.0001) at the maximum load. Systolic and diastolic arterial pressures were not associated with the timolol concentration.
CONCLUSION: The plasma concentration of ophthalmic timolol correlates with several haemodynamic effects. As HR decreases, SVRI increases and blood pressure is kept unchanged.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15912390     DOI: 10.1007/s00228-005-0945-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Clinical pharmacokinetics of beta-adrenoreceptors blockers.

Authors:  G Johnsson; C G Regårdh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension.

Authors:  R G Asmar; J C Kerihuel; X J Girerd; M E Safar
Journal:  Am J Cardiol       Date:  1991-07-01       Impact factor: 2.778

3.  Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel.

Authors:  J Niño; K Tahvanainen; H Uusitalo; V Turjanmaa; N Hutri-Kähönen; T Kaila; A Ropo; T Kuusela; M Kähönen
Journal:  Clin Physiol Funct Imaging       Date:  2002-07       Impact factor: 2.273

4.  Non-invasive continuous finger blood pressure measurement during orthostatic stress compared to intra-arterial pressure.

Authors:  B P Imholz; J J Settels; A H van der Meiracker; K H Wesseling; W Wieling
Journal:  Cardiovasc Res       Date:  1990-03       Impact factor: 10.787

5.  Influences of nonselective, beta(1)-selective and vasodilatory beta(1)-selective beta-blockers on arterial pulse wave velocity in normotensive subjects.

Authors:  M Kahonen; R Ylitalo; T Koobi; V Turjanmaa; P Ylitalo
Journal:  Gen Pharmacol       Date:  2000-10

6.  Effect of coenzyme Q10 on hemodynamic response to ocular timolol.

Authors:  N Takahashi; T Iwasaka; T Sugiura; H Onoyama; S Kurihara; M Inada; H Miki; M Uyama
Journal:  J Cardiovasc Pharmacol       Date:  1989-09       Impact factor: 3.105

7.  Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.

Authors:  Issam Zineh; Amber L Beitelshees; Andrea Gaedigk; Joseph R Walker; Daniel F Pauly; Kathleen Eberst; J Steven Leeder; Michael S Phillips; Craig A Gelfand; Julie A Johnson
Journal:  Clin Pharmacol Ther       Date:  2004-12       Impact factor: 6.875

8.  Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily.

Authors:  A H Shedden; J Laurence; A Barrish; T V Olah
Journal:  Doc Ophthalmol       Date:  2001-07       Impact factor: 2.379

9.  Effect of topical timolol maleate on exercise performance.

Authors:  W J Doyle; P A Weber; R H Meeks
Journal:  Arch Ophthalmol       Date:  1984-10

10.  Timolol: long-term Canadian multicentre study.

Authors:  R P LeBlanc; N E Saheb; G Krip
Journal:  Can J Ophthalmol       Date:  1985-06       Impact factor: 1.882

View more
  10 in total

1.  Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.

Authors:  Tuomo Nieminen; Hannu Uusitalo; Jukka Mäenpää; Väinö Turjanmaa; Anders Rane; Stefan Lundgren; Auli Ropo; Riikka Rontu; Terho Lehtimäki; Mika Kähönen
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

2.  Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.

Authors:  Aswani Dutt Vadlapudi; Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Recent Pat Biomed Eng       Date:  2012-04-01

3.  Hypotensive potential of sildenafil and tamsulosin during orthostasis.

Authors:  Tuomo Nieminen; Tiit Kööbi; Teuvo L J Tammela; Mika Kähönen
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

4.  Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma.

Authors:  Ciro Costagliola; Francesco Parmeggiani; Gianni Virgili; Giuseppe Lamberti; Carlo Incorvaia; Paolo Perri; Claudio Campa; Adolfo Sebastiani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-11-15       Impact factor: 3.117

5.  Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma.

Authors:  Matthias Huber; Marita Kölzsch; Ralf Stahlmann; Werner Hofmann; Juliane Bolbrinker; Dagmar Dräger; Reinhold Kreutz
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

6.  Association between Ophthalmic Timolol and Hospitalisation for Bradycardia.

Authors:  Nicole L Pratt; Emmae N Ramsay; Lisa M Kalisch Ellett; Tuan A Nguyen; Elizabeth E Roughead
Journal:  J Ophthalmol       Date:  2015-03-22       Impact factor: 1.909

7.  A comparative study on efficacy of fixed combination timolol/brinzolamide versus travoprost monotherapy in drug-naïve open-angle glaucoma patients.

Authors:  Alok Dixit; Atul Ashish; Reena Sharma
Journal:  Ther Adv Ophthalmol       Date:  2020-04-28

8.  From Eye Drops to ICU, a Case Report of Three Side Effects of Ophthalmic Timolol Maleate in the Same Patient.

Authors:  Muhammad Asim Rana; Ahmed Fouad Mady; Basheer Abdel Rehman; Abdulrahman Alharthy; Basim Huwait; Asim Riaz; Waleed Tharwat Aletreby
Journal:  Case Rep Crit Care       Date:  2015-08-06

9.  Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study.

Authors:  Anthony P Khawaja; Michelle P Y Chan; David C Broadway; David F Garway-Heath; Robert Luben; Jennifer L Y Yip; Shabina Hayat; Nicholas J Wareham; Kay-Tee Khaw; Paul J Foster
Journal:  Ophthalmology       Date:  2014-04-02       Impact factor: 12.079

10.  Ophthalmic Timolol and Hospitalization for Symptomatic Bradycardia and Syncope: A Case Series.

Authors:  Syed A Abbas; Syeda M Hamadani; Umair Ahmad; Aditi Desai; Karishma Kitchloo
Journal:  Cureus       Date:  2020-03-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.